Wednesday, April 10, 2019, Anaheim, California, 6:00 PM – 8:00 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 2 — Hodgkin and Non-Hodgkin Lymphomas

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:00 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Christopher R Flowers, MD, MS
Professor, Hematology and Medical Oncology
Director, Emory Lymphoma Program
Scientific Director, Winship Research Informatics
Winship Cancer Institute
Atlanta, Georgia

Amy Goodrich, CRNP
Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine
Baltimore, Maryland

Patrick B Johnston, MD, PhD
Consultant in Hematology and Blood
and Marrow Transplant
Mayo Clinic
Rochester, Minnesota

Robin Klebig, APRN, CNP, AOCNP
Nurse Practitioner
Division of Hematology, Lymphoma Group
Mayo Clinic
Rochester, Minnesota

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Seattle Genetics during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
5:30 PM – 6:00 PM – Registration and Dinner Buffet
6:00 PM – 8:00 PM – Educational Program

Module 1: Clinical Considerations in the Management of Newly Diagnosed and Progressive Hodgkin Lymphoma (HL)


  • Relative benefits and risks of various combination chemotherapy regimens for newly diagnosed advanced-stage HL
  • Clinical implications of the recent FDA approval of brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine (AVD) as first-line therapy for advanced classical HL
  • Incidence and management of peripheral neuropathy and other toxicities associated with BV in HL
  • Use of nonchemotherapy approaches for elderly patients and those with preexisting comorbidities
  • Biologic rationale for the efficacy of immune checkpoint inhibitors in HL and integration of nivolumab and pembrolizumab into the treatment algorithm for relapsed/refractory disease
  • Counseling patients receiving immune checkpoint inhibitor therapy on the potential for immune-related adverse events

Module 2: Sequence and Selection of Systemic Therapy for Patients with Newly Diagnosed and Relapsed/Refractory Follicular Lymphoma (FL)


  • Selection of treatment, including “watch and wait” and rituximab monotherapy, for patients with newly diagnosed FL
  • Integration of obinutuzumab-based induction and maintenance therapy for patients with previously untreated FL
  • Available data with the R-squared regimen of lenalidomide/rituximab in newly diagnosed FL; clinical and research implications
  • Comparative tolerability of R-squared and rituximab/chemotherapy in patients with previously untreated FL
  • Research results with R-squared for patients with relapsed/refractory FL; current clinical role of R-squared for patients with relapsed/refractory disease
  • Appropriate integration of idelalisib, copanlisib and duvelisib into current management algorithms
  • Recognition, prevention and management of PI3 kinase inhibitor-associated toxicities in patients with relapsed/refractory FL

Module 3: Protocol and Nonresearch Care of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)


  • Molecular subtypes of DLBCL and effect on prognosis and potential treatment course
  • Management of relapsed/refractory disease, including the use of lenalidomide
  • Available data with and optimal integration of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory DLBCL; practical considerations in the administration of CAR T-cell therapy`
  • Available data with the use of anti-PD-1/PD-L1 antibodies in patients with relapsed/refractory disease; clinical trial findings supporting the FDA approval of pembrolizumab for relapsed/refractory primary mediastinal large B-cell lymphoma
  • Novel agents and strategies, including polatuzumab vedotin, currently under investigation in relapsed/refractory DLBCL

Module 4: Novel Agents and Promising Investigational Strategies for Patients with Mantle Cell Lymphoma (MCL)


  • Sequencing of available treatment options for relapsed/refractory MCL: acalabrutinib, bortezomib, lenalidomide, ibrutinib, et cetera
  • Optimal integration of lenalidomide into treatment algorithms for patients with relapsed/refractory MCL; practical considerations, including use of prophylactic anticoagulation or antiplatelet therapy, for patients about to commence lenalidomide treatment
  • Research database supporting the FDA approval of acalabrutinib in relapsed/refractory MCL; patient selection for its use in clinical practice
  • Counseling patients receiving oral therapies regarding adherence
  • Emerging efficacy and safety data and potential nonresearch role of venetoclax — alone or in combination with ibrutinib — for MCL

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), and use this information to enhance decision-making for patients diagnosed with these diseases.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies for FL, MCL, DLBCL and HL to support quality of life and continuation of therapy.
  • Recall the biologic rationale for, available research data with and ongoing research efforts evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive FL and MCL, and use this information to guide protocol and off-protocol care for these patients.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R DLBCL and other lymphomas for whom this approach may be appropriate.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for FL, MCL, DLBCL and HL, and, where applicable, refer eligible patients for trial participation.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 2 contact hours is provided by RTP.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Seattle Genetics.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 2 — Hodgkin and Non-Hodgkin Lymphomas. Onsite registration will be open starting at 5:30 PM on Wednesday, April 10, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.